Melanoma & Skin Cancer | Specialty

The OncLive Melanoma & Skin Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of skin cancers, including melanoma, basal cell carcinoma, and more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in melanoma and other skin cancers.

Atezolizumab Plus Cobimetinib/Vemurafenib Meets PFS Endpoint in Frontline BRAF V600+ Advanced Melanoma

December 13th 2019

The triplet regimen of atezolizumab, cobimetinib, and vemurafenib was found to improve progression-free survival compared with cobimetinib/vemurafenib plus placebo in patients with previously untreated BRAF V600 mutation–positive advanced melanoma.

Dr. Marron on Shortening Treatment Duration of Immunotherapy in Melanoma

December 12th 2019

Thomas Marron, MD, PhD, discusses the potential benefit of shortening the length of immunotherapy treatment in melanoma.

The New Horizon in Melanoma

December 11th 2019

Jeffrey S. Weber, MD, PhD, looks to earlier use of immunotherapy and novel combinations in melanoma.

Dr. Daud on Dabrafenib/Trametinib Vs Immunotherapy in Melanoma

December 5th 2019

Adil Daud, MD, discusses the combination of dabrafenib and trametinib versus immunotherapy in patients with BRAF V600-mutant metastatic melanoma.

Spartalizumab Plus Dabrafenib/Trametinib Impresses in BRAF+ Melanoma With Poor Prognosis

November 27th 2019

A triplet combining the PD-1 inhibitor spartalizumab with dabrafenib and trametinib led to a 12-month overall survival rate of 86.1% for patients with previously untreated advanced BRAF V600–mutant melanoma.

Expert Weighs in on Targeted and Immunotherapy Combinations in Melanoma

November 26th 2019

Ryan J. Sullivan, MD, discusses the rationale for BRAF/MEK combinations and immunotherapeutic combinations in melanoma and ongoing research examining triplet regimens.

Expert Highlights Potential Markers of Nivolumab/Ipilimumab Response in Melanoma

November 26th 2019

Georgina V. Long, BSc, PhD, MBBS, FRACP, discusses the findings from a subgroup analyses of the CheckMate-067 trial.

Cobimetinib/Vemurafenib OS Benefit Sustained at 5 Years in BRAF+ Melanoma

November 25th 2019

The combination of cobimetinib (Cotellic) and vemurafenib (Zelboraf) maintained an advantage for overall survival and objective response rate in patients with BRAF-positive melanoma versus vemurafenib alone.

CR With Dabrafenib/Trametinib Linked to Long-Term Survival in BRAF+ Melanoma

November 24th 2019

Patients with unresectable or metastatic BRAF V600-mutant melanoma who achieve a complete response to dabrafenib (Tafinlar) plus trametinib (Mekinist) are more likely to have improved survival outcomes at 5 years.

Dr. Glitza on Intrathecal Nivolumab Approaches in Leptomeningeal Disease

November 24th 2019

Isabella C. Glitza, MD, discusses a single-center phase I/Ib trial of concurrent intravenous and intrathecal nivolumab for patients with metastatic melanoma and leptomeningeal disease.

Dr. McArthur Discusses Subpopulation Data from coBRIM Trial in Advanced Melanoma

November 23rd 2019

Grant McArthur, PhD, discusses significant results from the final analysis of the coBRIM trial, which evaluated the 5-year survival data of cobimetinib plus vemurafenib in patients with BRAF V600-mutated advanced melanoma.

Neoadjuvant T-VEC May Improve Survival in Advanced Melanoma

November 23rd 2019

Talimogene laherparepvec (T-VEC; Imlygic) prior to surgery was associated with improved recurrence-free survival and overall survival compared with surgery alone in patients with resectable advanced melanoma.

Dr. Sullivan Discusses Role of Dabrafenib Plus Trametinib in Melanoma

November 23rd 2019

Ryan J. Sullivan, MD, discusses the significance of the BRAF/MEK combination dabrafenib and trametinib, which was the first BRAF/MEK inhibitor regimen to be approved by the FDA for the treatment of patients with BRAF V600E–positive stage III melanoma following complete resection.

Targeted Combos Improve OS in Melanoma, But Mitigating Toxicities Essential

November 23rd 2019

Adil Daud, MD, discusses the role of dabrafenib plus trametinib in patients with advanced melanoma and highlighted other combinations under investigation.

Dr. Weber on Adjuvant Pembrolizumab in Melanoma

November 23rd 2019

Jeffrey S. Weber, MD, PhD, discusses the phase III EORTC1325/KEYNOTE-054 trial, which looked at adjuvant pembrolizumab in patients with stage III melanoma.

Frontline Nivolumab/Ipilimumab Combo Delivers Long-Term OS Advantage in Melanoma

November 23rd 2019

The combination of nivolumab (Opdivo) and ipilimumab (Yervoy) showed a sustained survival benefit compared with nivolumab or ipilimumab alone, according to 5-year follow-up results.

Dr. Danuser Discusses Impact of RacP29S Mutation in Melanoma

November 22nd 2019

Gaudenz Danuser, PhD, discusses how the activation of RacP29S impacts the treatment of patients with melanoma. His lab has been studying the Rac molecule for around 20 years. The RacP29S mutation most commonly appears in melanoma, but it has since been discovered in a few other cancer types as well.

Combination BRAF/MEK Inhibition Induces Potent Antitumor Activity in NRAS+ Melanoma

November 22nd 2019

Combining a BRAF inhibitor with a MEK inhibitor causes endoplasmic reticulum stress in BRAF wild-type, NRAS-mutated melanoma cells, resulting in significant antitumor activity.

Dr. Warner Discusses Findings from COMBI-i Trial in Melanoma

November 22nd 2019

Allison Betof Warner, MD, PhD, discusses the excitement surrounding the findings from the COMBI-i trial that was presented at the 2019 ASCO Annual Meeting. This trial investigated the combination of PD-1 inhibitor spartalizumab with dabrafenib plus trametinib in patients with advanced BRAF V6000mutant melanoma.

Dr. Shoushtari on the Data from the First-in-Human Trial for Tebentafusp in Advanced Melanoma

November 22nd 2019

Alexander N. Shoushtari, MD, discusses the significance of the findings from the first-in-human trial evaluating tebentafusp, a TCR–CD3 bispecific, in patients with advanced melanoma.